863456-50-2

Usage

Uses

Used in Pharmaceutical Industry:
Suberoylanilide Hydroxamic Acid b-D-Glucuronide is used as a pharmaceutical agent for its potential therapeutic effects. As a metabolite of SAHA, it may exhibit similar properties and contribute to the treatment of various diseases, particularly cancer.
Used in Research and Development:
In the field of research and development, Suberoylanilide Hydroxamic Acid b-D-Glucuronide serves as a valuable compound for studying the metabolism, pharmacokinetics, and pharmacodynamics of SAHA. This knowledge can help in the development of more effective drugs and therapies.
Used in Drug Delivery Systems:
Suberoylanilide Hydroxamic Acid b-D-Glucuronide can be employed in drug delivery systems to improve the bioavailability and therapeutic efficacy of SAHA. By incorporating this metabolite into novel drug delivery platforms, researchers can enhance the drug's performance and target specific diseases more effectively.
Used in Quality Control and Analysis:
In the pharmaceutical industry, Suberoylanilide Hydroxamic Acid b-D-Glucuronide can be utilized for quality control and analysis purposes. Its unique chemical properties allow for accurate detection and quantification, ensuring the purity and potency of SAHA-based drugs.

Upstream product

• 21085-72-3 1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester 
• 319926-19-7 (2S,3S,4S,5R,6S)-3,4,5-triacetoxy-6-(1,3-dioxo-1,3-dihydro-isoindol-2-yloxy)-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 319926-20-0 (2S,3S,4S,5R,6S)-3,4,5-Triacetoxy-6-aminooxy-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 931415-42-8 methyl 2,3,4-tri-O-acetyl-1-O-7-(phenylcarbamoyl)hepthydroxamoyl-β-D-glucopyranosyluronate 
• 931415-44-0 3,4,5-trihydroxy-6-(7-phenylcarbamoyl-heptanoylaminooxy)-tetrahydro-pyran-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) β-glucuronide and β-galactoside for application in selective prodrug chemotherapy

The β-O-glucuronide and β-O-galactoside of SAHA have been prepared and evaluated as prodrugs for selective cancer chemotherapy (ADEPT, PMT). These new compounds are stable under physiological conditions and do not exhibit any antiproliferative activity co